Association of dopamine agonist use with impulse control disorders in Parkinson disease

被引:475
|
作者
Weintraub, Daniel
Siderowf, Andrew D.
Potenza, Marc N.
Goveas, Joseph
Morales, Knashawn H.
Duda, John E.
Moberg, Paul J.
Stern, Matthew B.
机构
[1] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[4] Vet Affairs Med Ctr, Educ & Clin Ctr, Philadelphia, PA USA
[5] Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[6] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA
关键词
D O I
10.1001/archneur.63.7.969
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD). Design: An unstructured screening interview for ICDs (compulsive gambling, buying, and sexual behavior) followed by a telephone-administered structured interview for screen- positive patients. Setting: Two university-affiliated movement disorders centers. Participants: A convenience sample of 272 patients with idiopathic PD who were screened for psychiatric complications. Main Outcome Measures: Presence of compulsive gambling, buying, or sexual behavior as assessed by the Minnesota Impulsive Disorders Interview. Results: Eighteen patients (6.6%) with PD met criteria for an ICD at some point during the course of PD, including (4.0%) with an active ICD. Compulsive gambling and compulsive sexual behavior were equally common. In a multivariate model, treatment with a dopamine agonist (P = .01) and a history of ICD symptoms prior to PD onset (P = .02) predicted current ICD. There were no differences between the dopamine agonists in their association with ICDs (P = .21), and daily doses of dopamine agonists were higher in patients with an ICD than in dopamine agonist-treated patients without an ICD (P < .001). Conclusions: Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically. Because dopamine agonists are increasingly being used for other indications, future research should assess the dopamine agonist-associated risk for ICDs in other populations.
引用
收藏
页码:969 / 973
页数:5
相关论文
共 50 条
  • [1] Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson's disease
    Corvol, J. C.
    Artaud, F.
    Rascol, O.
    Durif, F.
    Derkinderen, P.
    Bourdain, F.
    Brandel, J. -P.
    Pico, F.
    Lacomblez, L.
    Bonnet, C.
    Grabli, D.
    Klebe, S.
    Mangone, G.
    You, H.
    Mesnage, V.
    Lee, P. C.
    Brice, A.
    Vidailhet, M.
    Cormier-Dequaire, F.
    Elbaz, A.
    MOVEMENT DISORDERS, 2017, 32
  • [2] Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
    Staubo, Sara C.
    Fuskevag, Ole Martin
    Toft, Mathias
    Lie, Ingeborg H.
    Alvik, Kirsti M. J.
    Jostad, Pal
    Tingvoll, Stein H.
    Lilleng, Hallvard
    Rosqvist, Kristina
    Storset, Elisabet
    Odin, Per
    Dietrichs, Espen
    Dietrichs, Erik Sveberg
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (02)
  • [3] The use of a dopamine agonist as the initial treatment in Parkinson's disease does not predict the development of impulse control disorders
    Cervantes-Arriaga, A.
    Rodriguez-Violante, M.
    Velazquez-Osuna, S.
    Gonzalez-Latapi, P.
    Camacho-Ordonez, A.
    MOVEMENT DISORDERS, 2014, 29 : S312 - S312
  • [4] Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease
    Fenu, Sandro
    Wardas, Jadwiga
    Morelli, Micaela
    BEHAVIOURAL PHARMACOLOGY, 2009, 20 (5-6): : 363 - 379
  • [5] Dopamine and Impulse Control Disorders in Parkinson's Disease
    Weintraub, Daniel
    ANNALS OF NEUROLOGY, 2008, 64 (06) : S93 - S100
  • [6] Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease
    Valenca, Guilherme T.
    Glass, Philip G.
    Negreiros, Nadja N.
    Duarte, Meirelayne B.
    Ventura, Lais M. G. B.
    Mueller, Mila
    Oliveira-Filho, Jamary
    PARKINSONISM & RELATED DISORDERS, 2013, 19 (07) : 698 - 700
  • [7] Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease
    Joutsa, Juho
    Martikainen, Kirsti
    Vahlberg, Tero
    Kaasinen, Valtteri
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (10) : 1079 - 1083
  • [8] Screening for impulse control disorders in Parkinson’s disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors
    Manuela Contin
    Giovanna Lopane
    Luca Marini
    Susan Mohamed
    Luisa Sambati
    Patrizia De Massis
    Maria Guarino
    Simonetta Sermi
    Chiara Persichella
    Pietro Cortelli
    Giovanna Calandra-Buonaura
    Neurological Sciences, 2023, 44 : 565 - 572
  • [9] Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors
    Contin, Manuela
    Lopane, Giovanna
    Marini, Luca
    Mohamed, Susan
    Sambati, Luisa
    De Massis, Patrizia
    Guarino, Maria
    Sermi, Simonetta
    Persichella, Chiara
    Cortelli, Pietro
    Calandra-Buonaura, Giovanna
    NEUROLOGICAL SCIENCES, 2023, 44 (02) : 565 - 572
  • [10] Dopamine agonists and impulse control disorders in Parkinson's disease
    MacMahon, Douglas G.
    Macphee, Graeme J. A.
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2008, 12 (09) : 5 - +